LEN vs RYTM · rev $34.19B vs rev $130.1M
LEN (LEN) versus Rhythm Pharmaceuticals Inc (RYTM) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Rhythm Pharmaceuticals Inc (RYTM) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported RYTM revenue for 2024-12-31 was $130.1M. Net income was -$260.6M. Revenue was up 68.1% from 2023-12-31 to 2024-12-31. RYTM currently screens at market cap $6.49B.
LEN currently screens at market cap $0. RYTM currently screens at market cap $6.49B.
Not investment advice. Open the LEN and RYTM stock pages for the full models.
Not investment advice.